Penn Medicine Provider
Hematology, Medical Oncology
Douglas F. Beach, MD
4.9
(708)
Accepting new patients
Sees patients age 18 and up
Penn Hematology/Oncology Pennsylvania Hospital

About me

  • Director, CREP/Breast and Ovarian Cancer Program
  • Associate Program Director, Internal Medicine Residency
  • Clinical Associate Professor of Medicine (Hematology-Oncology)

Education and training

  • Medical School: University of Medicine and Dentistry of New Jersey
  • Residency: Cooper University Hospital
  • Fellowship: Cooper University Hospital

What my patients think about me

Average Rating
4.9

709 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

June 2025
5.0
5.0
knowledgeable
May 2025
5.0
5.0
provider is very good
May 2025
5.0
5.0
he is very thorough.
May 2025
5.0
5.0
dr.beach is awesome!!!

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Beach is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Wojciech Jurczak, MD PhD, Ryan W. Jacobs, MD, Sebastian Grosicki, MD PhD, Krzysztof Giannopoulos, MD PhD, Tomasz Wrobel, MDPhD, Syed F. Zafar, MD, Jennifer L. Cultrera, MD, Suman Kambhampati, MD, Alexey Danilov, MD, John M. Burke, MD, Jerome Goldschmidt, MD, Douglas F. Beach, MD, Scott F. Huntington, MD MPH, Javier Pinilla Ibarz, MD PhD, Jeff P Sharman, MD, Tanya Siddiqi, MD, Danielle M. Brander, MD, John M. Pagel, MDPhD, Kathryn S. Kolibaba, MD, Monika Dlugosz-Danecka, MD PhD, Nilanjan Ghosh, MD PhD, Peter Sportelli, BS, Hari P. Miskin, MSc, Owen A. O'Connor, MD PhD, Michael S. Weiss, Ian W. Flinn, MD PhD Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study , Blood (2020) 136 (Supplement 1): 37–39, 136: 2020,37–39


Riley SV, Beach DF. Making Progress: Impact of Diabetes on Metastatic Colon Cancer Disease Progression. , J. Neoplasm. , 5(1:1): 2020


Mato, A. R., Roeker, L. E., Allan, J. N., Pagel, J. M., Brander, D. M., Hill, B. T., Cheson, B. D., Furman, R. R., Lamanna, N., Tam, C. S., Handunnetti, S., Jacobs, R., Lansigan, F., Bhavsar, E., Barr, P. M., Shadman, M., Skarbnik, A. P., Goy, A., Beach, D. F., Svoboda, J., Pu, J. J., Sehgal, A. R., Zent, C. S., Tuncer, H. H., Schuster, S. J., Pickens, P. V., Shah, N. N., Rhodes, J., Ujjani, C. S., Nabhan, C. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. , Am J Hematol, 93(11): 2018,1394-1401


Oren O, Oren M, Beach D On the generalizability of prostate cancer studies: why race matters. , Ann Oncol , 27(12): 2016,2146-2148


Grant S, Meykler S, Beach D Superior vena cava syndrome as an initial presentation of low-grade follicular lymphoma. , J Community Support Oncol , 12(11): 2014,415-417


Beach DF, Barnoski B, Patel V, Schwarting R, Strair R, Lachant N Duplication of chromosome 1 [dup(1)(q21q32)] as the sole cytogenetic abnormality in a patient previously treated for AML. , Cancer Genetics, 205(12): 2012,665-668


Beach DF, Klump W, Haddad G, Reid LM, Schwarting R, Hageboutros A. Extrapulmonary small cell: a novel case of small cell carcinoma of the thyroid gland. , Medical Oncology, 29(3): 2012,1405-1408


Beach D, Somer R Metastatic Renal Cell Carcinoma to the Phalanx. , Urology, 79(5): 2012,e77


Beach-Rak Medicine LLC Master Diagnostician Series: Acute Kidney Injury , iPhone application for diagnosing and managing AKI. : 2012


Beach DF, Somer R A Wealth of New Options: A Case Presentation of the Management of Castration-Recurrent Prostate Cancer , Seminars in Oncology, 39(1): 2012,1-8